CRYOPORT, INC. Deferred Income Tax Expense (Benefit)
CRYOPORT, INC. (CYRX) reported Deferred Income Tax Expense (Benefit) of $503.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-06
- CRYOPORT, INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was $267.00K, a 75.79% decline year-over-year.
- CRYOPORT, INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $236.00K.
- CRYOPORT, INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$117.00K, a 2050.00% decline year-over-year.
- CRYOPORT, INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$299.00K, a 146.79% decline year-over-year.
- CRYOPORT, INC. deferred income tax expense (benefit) for fiscal 2025 was $661.00K.
- CRYOPORT, INC. deferred income tax expense (benefit) for fiscal 2024 was -$377.00K.
- CRYOPORT, INC. deferred income tax expense (benefit) for fiscal 2023 was -$1.98M.
- CRYOPORT, INC. deferred income tax expense (benefit) for fiscal 2022 was -$411.00K, a 277.92% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 3 month as first filed | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 6 month as first filed | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 9 month as first filed | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $267.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $503.00K 10-Q · filed 2026-08-06 | $386.00K derived: sum of 3 quarters · filed 2026-08-06 | $87.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $236.00K 10-Q · filed 2026-05-05 | $119.00K derived: sum of 2 quarters · filed 2026-05-05 | -$180.00K derived: sum of 3 quarters · filed 2026-05-05 | $923.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$416.00K derived: sum of 2 quarters · filed 2026-03-05 | $687.00K derived: sum of 3 quarters · filed 2026-08-06 | $661.00K 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | -$299.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $804.00K derived: sum of 2 quarters · filed 2026-08-06 | $778.00K 10-Q · filed 2025-11-06 | $784.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.08M 10-Q · filed 2026-08-06 | $1.08M derived: sum of 3 quarters · filed 2026-08-06 | $1.72M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$26.00K 10-Q · filed 2026-05-05 | -$20.00K derived: sum of 2 quarters · filed 2026-05-05 | $619.00K derived: sum of 3 quarters · filed 2026-05-05 | $148.00K derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $645.00K derived: sum of 2 quarters · filed 2026-03-05 | $174.00K derived: sum of 3 quarters · filed 2026-03-05 | -$377.00K 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $639.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $168.00K derived: sum of 2 quarters · filed 2025-11-06 | -$383.00K 10-Q · filed 2025-11-06 | -$2.17M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | -$471.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.02M 10-Q · filed 2025-08-12 | -$2.81M derived: sum of 3 quarters · filed 2026-03-05 | |||||
| 2024-03-31 | -$551.00K 10-Q · filed 2025-05-08 | -$2.34M derived: sum of 2 quarters · filed 2026-03-05 | ||||||
| 2023-12-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.98M 10-K · filed 2026-03-05 | ||||||
| 2023-09-30 | -$190.00K 10-Q · filed 2024-11-07 | |||||||
| 2023-03-31 | $246.00K 10-Q · filed 2023-05-04 | $804.00K derived: sum of 2 quarters · filed 2025-03-07 | $316.00K derived: sum of 3 quarters · filed 2025-03-07 | -$225.00K derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | $558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $70.00K derived: sum of 2 quarters · filed 2025-03-07 | -$471.00K derived: sum of 3 quarters · filed 2025-03-07 | -$411.00K 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | -$488.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$1.03M derived: sum of 2 quarters · filed 2022-11-04 | -$969.00K 10-Q · filed 2022-11-04 | -$1.61M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-06-30 | -$541.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$481.00K 10-Q · filed 2022-08-04 | -$1.12M derived: sum of 3 quarters · filed 2023-05-04 | -$355.00K derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2022-03-31 | $60.00K 10-Q · filed 2023-05-04 | -$582.00K derived: sum of 2 quarters · filed 2023-05-04 | $186.00K derived: sum of 3 quarters · filed 2023-05-04 | $211.00K derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | -$642.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $126.00K derived: sum of 2 quarters · filed 2023-02-28 | $151.00K derived: sum of 3 quarters · filed 2023-02-28 | $231.00K 10-K · filed 2023-02-28 | ||||
| 2021-09-30 | $768.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $793.00K derived: sum of 2 quarters · filed 2022-11-04 | $873.00K 10-Q · filed 2022-11-04 | $347.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $105.00K 10-Q · filed 2022-08-04 | -$421.00K derived: sum of 3 quarters · filed 2023-02-28 | -$430.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $80.00K 10-Q · filed 2022-05-05 | -$446.00K derived: sum of 2 quarters · filed 2023-02-28 | -$455.00K derived: sum of 3 quarters · filed 2023-02-28 | -$428.00K derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | -$526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$535.00K derived: sum of 2 quarters · filed 2023-02-28 | -$508.00K derived: sum of 3 quarters · filed 2023-02-28 | -$499.00K 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $18.00K derived: sum of 2 quarters · filed 2021-11-04 | $27.00K 10-Q · filed 2021-11-04 | $27.01K 10-Q · filed 2020-11-06 | $48.00K derived: sum of 4 quarters · filed 2021-11-04 | |||
| 2020-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $36.00K 10-Q · filed 2021-08-06 | $36.01K 10-Q · filed 2020-08-10 | $57.00K derived: sum of 3 quarters · filed 2021-08-06 | $57.00K derived: sum of 4 quarters · filed 2021-08-06 | |||
| 2020-03-31 | $9.00K 10-Q · filed 2021-05-06 | $9.00K 10-Q · filed 2020-05-08 | $30.00K derived: sum of 2 quarters · filed 2021-05-06 | $30.00K derived: sum of 3 quarters · filed 2021-05-06 | $30.00K derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $21.00K derived: sum of 2 quarters · filed 2021-03-01 | $21.00K derived: sum of 3 quarters · filed 2021-03-01 | $21.00K 10-K · filed 2021-03-01 | $20.93K 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | |||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-08 | |||||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-10 | |||||||
| 2017-12-31 | $0.00 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |